B of A Securities Maintains Underperform on Sage Therapeutics, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has maintained an 'Underperform' rating on Sage Therapeutics and lowered its price target from $11 to $6.
October 09, 2024 | 5:42 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
B of A Securities has maintained an 'Underperform' rating on Sage Therapeutics and reduced its price target from $11 to $6, indicating a negative outlook.
The 'Underperform' rating and significant reduction in price target from $11 to $6 by B of A Securities suggest a negative outlook for Sage Therapeutics. This could lead to a decrease in investor confidence and a potential drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100